Reserved
area
If you do not have user and password contact us

About us

LOFARMA IS A LEADING PHARMACEUTICAL COMPANY

performing research, development, production and marketing activities in the field of specific immunotherapy and diagnostics for the treatment and prevention of allergic diseases.

Over the years we have gained know-how and taken young human resources on board thus enabling us to tackle scientific and regulatory challenges and see this innovative and consolidated Italian pharmaceutical company grow.

 

LOFARMA IS INTERNATIONAL:

Lofarma is now a multinational company operating in Germany, Portugal, Spain, the United Kingdom, Greece, Bulgaria, Hungary, Albania, South Korea, Mexico, Mongolia and Russia.

 

SUBSIDIARIES 

Lofarma Deutschland GmbH www.lofarma.de

Lofarma Lusitana Lda lofarmaportugal@gmail.com

Lofarma Iberica customer@lofarma.es

 

DISTRIBUTORS

South Korea www.lofarma.co.kr

Albania luan.lekli@leklipharma.com

Greece alexandrisgeorgios@hotmail.com

Hungary t.frank@frank-diagn.hu

Mexico www.yumkaa.com.mx

Russia www.allergen.ru

 

LOFARMA IS RESEARCH AND TECHNOLOGY:

Some product lines were created through a great commitment in the field of research and development, thanks to the availability of advanced technologies and unique departments, such as the Acarology Department, in which mites are bred and fed on a specific diet, unique of its kind, enabling a constant and quality production in compliance with Good Manufacturing Guidelines. The batches of mites produced are then analysed by the Quality Control Laboratory and divided into the final batches, intended for diagnostic and therapeutic use.

The knowledge we built up over time, has enabled Lofarma to produce numerous types of allergen immunotherapies and over 200 diagnostic tests for allergic diseases.

Allergen powder technology, developed by Lofarma, led to the creation of the carbamylated monomeric allergoid LAIS in tablet, a chemically modified allergen to be used for the treatment of allergies.

The success achieved with this technology, initially in tablets, enabled us to develop the monomeric allergoid LAIS in drops and injections as well.